Skip to main content
Premium Trial:

Request an Annual Quote

Delphic Acquires Dx Business of iQur

NEW YORK (GenomeWeb News) – Pharmacogenomics test developer and specialty lab company Delphic has acquired the diagnostics business of iQur.

London-based iQur specializes in liver diagnostics and therapies. Delphic, which also is based in London, said in a statement that the acquisition would enable it to "leverage its capabilities and infrastructure to offer improved services in infectious diseases to the clinical and clinical trials markets, and to access the growing market for blood-borne virus screening."

iQur will continue to supply its ELF liver fibrosis test, which measures three serum markers that have been shown to correlate with the level of liver fibrosis, in partnership with Siemens.

iQur said that it would now focus on its vaccines program targeted as hepatitis, other infections, and cancer.

Financial terms of the acquisition were not disclosed.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more